A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs DS-1205c (Primary) ; Osimertinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Inc
- 05 Feb 2018 Status changed from not yet recruiting to recruiting.
- 01 Dec 2017 Planned initiation date changed from 15 Oct 2017 to 15 Jan 2018.
- 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.